SAN DIEGO – Results for the quarter ended Sept. 30, 2025 from Medtrade exhibitor Resmed Inc. showed a 9% revenue increase. Net income for the quarter was $349 million and diluted earnings per share was $2.37.

Non-GAAP net income increased by 15 percent to $375 million, and non-GAAP diluted earnings per share increased by 16 percent to $2.55, predominantly attributable to strong sales growth and gross margin improvement.

Resmed’s chairman and CEO, Mick Farrell, issued the following statement:

“Our fiscal year 2026 is off to a strong start, with first-quarter performance reflecting continued progress toward our mission of helping people sleep better, breathe better and live longer and healthier, with care provided in their own home.

“We delivered 9% headline revenue growth year-over-year, with a very strong 280 basis points of non-GAAP gross margin expansion, resulting in double-digit bottom-line performance: 16% non-GAAP EPS growth. These results reinforce the success of our strategy to transform healthcare in the home with hardware, software and solutions that people love.

“As we advance through fiscal year 2026, we remain committed to ongoing operational excellence and strategic investment in innovation, ultimately delivering strong, sustainable, profitable growth as we provide access to life-changing care for the billions of people worldwide who need our market-leading healthcare solutions delivered right where they live.”

Operating cash flow for the quarter was $457 million, compared to net income in the current quarter of $349 million and non-GAAP net income of $375 million. During the quarter, Resmed paid $88 million in dividends to shareholders and repurchased 523,000 shares for consideration of $150 million as part of our ongoing capital management.